久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Zydus Cadila receives final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

expresspharmaJuly 05, 2021

Tag: Zydus , Emtricitabine , Tenofovir , HIV

Zydus Cadila has received final approval from the USFDA to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg, a company statement said.

Zydus Cadila receives final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

The drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in one’s body so that the immune system can work better.

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Previous:Adroit Biomed launches Glutone MD made from purest Setria Glutathione

Next:Bharat Biotech announces data from phase-III Covaxin clinical trials

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service